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Summary Forty-five patients with restrictive respiratory diseases, including thoracic
wall diseases (TWD, n ¼ 27) and neuromuscular diseases (NMD, n ¼ 18), underwent 18
months of home mechanical ventilation (HMV) treatment. Treatment consisted of a
two-level pressure system for 7 h at night, with oxygen available if needed.
Questionnaire-based assessments of health-related quality-of-life (HRQL) were
evaluated before treatment and at 3, 6, 9, 12 and 18 months of follow-up.
Hospitalization rates pre- and post-treatment were recorded, and the numbers need
to treat (NNT) to avoid hospitalization and absolute risk reduction (ARR) rates were
calculated. Several categories of HRQL, including physical function and vitality,
improved significantly with treatment in both groups of patients; these improvements
persisted over the entire 18 months. In contrast, other categories such as social
function and mental health improved initially and declined subsequently. Hospitaliza-
tions decreased significantly with treatment. NNT calculations indicated that
treatment would be needed for two TWD patients (ARR 63%) and one NMD patient
(ARR 78%) to prevent one hospitalization per year per disease group. We conclude
that improved quality-of-life and decreased hospitalizations make home non-invasive
mechanical ventilation an useful treatment for patients with restrictive respiratory
disorders.
& 2003 Published by Elsevier Ltd.
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Introduction
Home mechanical ventilation (HMV) has recently
become a widely available procedure for the
treatment of restrictive respiratory failure. In
patients with thoracic wall diseases (TWD), HMV
improves gas exchange, decreases dyspnoea and
increases lung muscle endurance and maximum
inspiratory pressure. However, some investigators
have reported that HMV may not modify lung
mechanics in those with neuromuscular diseases
(NMD).1–4 HMV, as it is known, also improves health-
related quality of life (HRQL) after 3 months of
treatment and reduces the number of hospitaliza-
tions due to respiratory failure.5–8
Questionnaires to assess HRQL include instru-
ments designed to solicit information on the overall
repercussion of a particular therapy or regimen on
the daily activity of the patients. However, the
magnitude of the changes in HRQL in relation to the
patients’ clinical changes following treatment with
HMV is not clearly known. The absolute risk
reduction (ARR) of adverse effects of a treatment
and its converse, the numbers needed to treat
(NNT) to avoid these effects, are tools that provide
a complete evaluation of the clinical significance
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and the magnitude of the changes achieved in the
patient’s HRQL.9,10
The objective of the present study was to
investigate the long-term effect of HMV on HRQL
and the rate of hospitalization. To evaluate the
efficacy of HMV treatment we also calculated the
ARR (i.e., aspects of the patient’s HRQL that
improve with HMV treatment) and the NNT (i.e.,
numbers of patients with restrictive pathology that
would require treatment with HMV to avoid
hospitalizations over a 1-year period).
Materials and methods
Patients
This was a prospective study of consecutive
patients referred to the Pneumology Department
of the University Hospital la Fe between January
1997 and November 2001 for evaluation for treat-
ment with HMV. The patients had moderate to
severe restrictive respiratory disorder resulting
from TWD or various NMD, and they were clinically
stable as defined by the absence of acute lung
infection in the 3 months before the study.
Informed consent was obtained from all patients.
HMV was initiated if, according to the established
consensus guidelines, the patients presented symp-
toms such as fatigue, dyspnoea, morning headache,
and one of the following criteria: diurnal Pa-
CO2445mm Hg, forced vital capacity o50% of
predicted in the NMD group ando40% of predicted
in the TWD group, maximum inspired pressure
o60 cm H2O, or oxygen saturation below 88% for
more than five consecutive minutes as measured by
nocturnal oximetry.11,12
Methods
The patients who fulfilled the criteria for inclusion
into the HMV program were hospitalized for 48–72 h
to fit to ventilation pressure systems and to assess
the HRQL before initiating therapy. HRQL was
evaluated using the Spanish validated version of
the SF36 questionnaire.13 This instrument contains
36 items grouped into eight domains:
1. Physical function: The grade of limitation of
routine daily activities (RDA) such as walking,
bathing, dressing or climbing stairs.
2. Physical role: The grade of limitation in RDA due
to physical problems.
3. Emotional role: The grade of emotional pro-
blems limiting RDA.
4. Pain: The presence of aches and pains in any part
of the body over the previous 4 weeks.
5. Vitality: The sensation of having energy or of
tiredness.
6. Social function: The grade limitations with
respect to relations with the family and friends.
7. Mental health: The presence of psychiatric
disturbances such as depression or anxiety.
8. General health: A subjective opinion of overall
health status.
Additionally, there was an independent category,
the ‘‘transition in health status’’, that can be
analysed as a quantitative variable providing
information on the changes in health status that
may have occurred between consecutive follow-up
visits.
The patients indicated their current state by
scoring each item from 0 to 100; lower scores
reflected increasing impairment or severity of
symptoms. For the ‘‘health transition’’ item, the
value was obtained as the difference between the
lower and the higher scores of successive follow-up
visits. The reference values for the Spanish
population, adjusted for age and sex, were
obtained from Alonso et al.14
Following the initial HRQL evaluation, the HMV
was initiated using a bi-level pressure ventilation
system (DP90s; Taema, Paris, France) with mini-
mum inspiratory pressure of 10 cm H2O and ex-
piratory pressure of 4 cm H2O. Commercial masks,
such as the Sullivans mask (Air Liquide Medicinal,
Paris-France) or the Adamss mask (Air Liquide
Medicinal, Paris-France), were used. Once the
patients were fitted to the HMV system and PaCO2
fell to a normal value or decreased at least 10mm
Hg, they were discharged from hospital. When the
patients did not show the improvement in PaCO2,
the pressures were gradually increased by 2 cm H2O
of inspiratory and/or expiratory pressure per day
until PaCO2 decreased 10mm Hg or returned to a
normal level. At this point, the patients were
discharged from hospital and instructed to continue
with the procedure for 7 h every night. An oxygen
supplement was made available for those patients
whose PaO2 was o55mm Hg.
The follow-up visits at 3, 6, 9, 12 and 18 months
were conducted in the outpatient clinic. HRQL was
evaluated at each visit. Adherence to treatment
was assessed through a weekly reading of the
timer-counter in the ventilator. The mechanical
functioning of the machine and the state of the
masks were checked regularly. The patients had
access to 24 h emergency telephone consultation. A
register of the number of hospitalizations for acute
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respiratory failure before and after the treatment
with HMV was maintained throughout the study.
Statistical analyses
All statistical analyses were performed using SPSS
version 10.0 for Windows 98. Comparisons between
groups of patients were performed with the
Student’s t-test. The pre- and post-HMV data of
the HRQL were analysed using ANOVA with the
Bonferroni correction. In those categories in which
statistically significant differences were encoun-
tered, the ARR (the greater value meant the better
result), its reciprocal (1/ARR) and the NNT (the
lower value meant the better result) were calcu-
lated. The number of hospitalizations pre- and
post-HMV was compared using the Student’s un-
paired t-test. All values of Po0:05 were considered
statistically significant.
Results
From the 67 patients (36 with TWD and 31 with
NMD) who started the study, 45 (27 with TWD
and 18 with NMD) completed the 18 months of
treatment. Twelve of the 22 remaining patients
(9 with amyotrophic lateral sclerosis and 3
with kyphoscoliosis) died during follow-up because
of acute respiratory failure (n ¼ 8) or community
acquired pneumonia (n ¼ 4); 10 patients (6
with TWD and 4 with NMD) abandoned the treat-
ment because of failure to fit to the ventilation
system.
The mean age of the 27 patients (16 men, 11
women) with TWD was 55.6 years. Diagnosis were:
kyphoscoliosis (n ¼ 22), fibrothorax (n ¼ 3) and
thoracoplasty (n ¼ 2). The mean age of the 18
patients (9 men, 9 women) with NMD was 42.5
years. Neuromuscular patients were: spinal atrophy
(n ¼ 1), Duchenne’s disease (n ¼ 5), amyotrophic
lateral sclerosis (ALS; n ¼ 3), Werdnig–Hoffman
disease (n ¼ 2), myasthenia gravis (n ¼ 2), Frie-
dreich’s ataxia (n ¼ 1), nemaline myopathy (n ¼ 1)
and Steinert disease (n ¼ 3).
As recorded on the machine’s timer-counter, the
patients used the HMV system for a mean of 6 h per
night. Oxygen supplementation was required during
the night in 19 cases (11 with TWD and 8 with NMD)
and was withdrawn later for most patients when
oxygen saturation had improved. Twenty patients,
mainly from the TWD group, used telephone
consultations.
Table 1 shows the baseline PaO2, PaCO2, SaO2 and
FVC in both groups. Table 2 summarizes the
baseline values of the HRQL domains in the two
groups of patients. The data indicate that, in both
types of pathology, most of the categories were
located between the 5th and 25th percentiles of
the reference population. The physical function
category in both groups of patients and the social
function domain in the males with TWD were lower
than the 5th percentile. Body pain and social
function categories in the women with TWD, and
body pain and mental health in the women with
NMD, were located between the 25th and 50th
percentiles. There were no significant differences
in either group in the domains of HRQL as a function
of gender.
Figures 1 and 2 show the changes in HRQL
categories at 3, 6, 9, 12 and 18 months of
treatment with HMV in the patients with TWD and
NMD, respectively. The patients with TWD pre-
sented significantly higher scores in physical func-
tion, physical capacity, vitality, emotional capacity
and health transition at 3 months of treatment;
these differences maintained over the 18 months of
treatment. Similarly, social function and mental
capacity improved significantly at the 6th month of
treatment, and began to diminish subsequently
from about 1 year of treatment, although these did
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Table 1 Mean (SD) values of lung function and nocturnal oxygen desaturation at baseline in patients with
thoracic wall diseases and neuromuscular diseases.
Thoracic wall diseases Neuromuscular diseases
Number of patients 27 18
FVC, % predicted 42.5 (18.5) 37.3 (19.6)
FEV1, % predicted 37.6 (9.1) 38.4 (20.8)
TLC % 63 (17.8) 53 (21.3)
% SaO2o88%n 42.2 (34.3) 27.1 (35.6)
PaO2, mm Hg 57.6 (8) 70.4 (15.3)
PaCO2, mm Hg 56.9 (11.3) 51.5 (11.7)
nNight-time percentage of SaO2o88%.
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not reach baseline values. In the patients
with NMD, the HRQL improved only in the cate-
gories of health transition and physical capacity at
3 months of treatment and, in the latter domain,
the improvement continued until 8 months of
treatment.
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Figure 1 Panels A–I show the changes in the various HRQL categories measured at follow-up in the patients with TWD.
Bars represent 95% confidence intervals. The horizontal axes, months of follow-up.
Table 2 Mean (SD) values of patients’ baseline scores measured on the SF-36 questionnaire upon entry into the
study.
Category Thoracic wall diseases Neuromuscular diseases
Men, n ¼ 16 Women, n ¼ 11 Men, n ¼ 9 Women, n ¼ 9
Physical function 34.1 (23.45) 23.2 (13.3) 12.7 (17.5) 26.1 (20.6)
Physical role 18.8 (29.6) 20.5 (29.2) 25.0 (33.1) 16.7 (25.0)
Pain 68.4 (35.8) 68.8 (33.8) 60.9 (33.0) 65.0 (35.8)
General health 47.4 (23.6) 42.8 (20.0) 41.0 (21.8) 41.4 (23.7)
Vitality 37.2 (24.1) 37.7 (20.4) 40.0 (17.3) 41.1 (24.6)
Social function 56.9 (40.2) 80.7 (26.4) 68.1 (34.3) 68.1 (34.3)
Emotional role 41.7 (49.4) 52.3 (43.5) 49.1 (45.0) 43.5 (47.5)
Mental health 51.8 (26.1) 45.5 (1.7) 51.1 (21.2) 59.1 (18.63)
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Tables 3 and 4 show the ARR and NNT for patients
with TWD and NMD, respectively. The ARR and NNT
were calculated in those domains of the HRQL
questionnaire that improved significantly during
the follow-up.
The number of hospitalizations decreased sig-
nificantly following HMV treatment in both groups
of patients. In the patients with TWD, the mean
annual rate of hospitalizations decreased from 1.52
hospitalizations per year before ventilation therapy
to 0.89 after it (P ¼ 0:002). The calculated ARR in
this group was 63% (range 26–100%) with two
patients needing treatment (range 1–4) to preclude
one hospitalization per year. The mean hospitaliza-
tion rate in the patients with NMD was 1.22 per year
before ventilation and 0.44 per year after HMV
therapy (P ¼ 0:001). The calculated ARR was 78%
(range 38–100%), and the NNT indicated one
patient needing treatment (range 1–3) to avoid
one hospitalization per year.
Discussion
The impact of HMV on the HRQL in patients with
restrictive respiratory diseases has been previously
evaluated,5–7 although the natural history of the
changes over time has not been fully studied. Our
results allow us to propose that HMV can have a
positive impact, with considerable clinical conse-
quences, on the patients undergoing this treat-
ment. In the present series of patients, HMV
improved the HRQL of patients with TWD even
over the short study period, and these changes
were maintained over a longer period. It appears to
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Figure 2 Panels A–I show the changes in the various HRQL categories measured at follow-up in the patients with
neuromuscular disease (NMD). Bars represent 95% confidence intervals. The horizontal axes, months of follow-up.
1324 R. Dom !enech-Clar et al.
be necessary to treat only a small number of
patients to elicit an improvement in various
categories of HRQL. The improvement in the HRQL
in the patients with NMD was not so readily
apparent. The rate of improvement in some HRQL
domains slowed over time, which corresponded to
disease progression, although the scores did not
achieve the pre-treatment level. However, the ARR
and NNT results indicate that the number of
patients requiring HMV to avoid one hospitalization
per year was lower in the NMD than in the TWD
group. The pre-existing differences in HRQL be-
tween the two groups before the therapy, together
with the heterogeneity and natural history of NMD
(especially of ALS), can explain the different
degrees of response to treatment observed be-
tween the patients with TWD and NMD. The
benefits of the HMV treatment in patients with
ARTICLE IN PRESS
Table 3 Results expressed as mean (95% confidence interval) of ARR and NNTat follow-up relative to baseline in
patients with thoracic wall diseases.
Category Follow-up time
3 months 6 months 9 months 12 months 18 months
Physical function
ARR 12% (5–20%) 14% (5–23%) 15% (6–23%) 12% (3–21%) 13% (5–21%)
NNT 8 (5–21) 7 (4–19) 7 (4–17) 8 (5–21) 8 (5–19)
Physical role
ARR 56% (38–74%) 70% (58–82%) 60% (40–80%) 55% (37–73%) 58% (40–77%)
NNT 2 (1–3) 1 (1–2) 2 (1–2) 2 (1–3) 2 (1–3)
Vitality
ARR 18% (9–27%) 25% (16–34%) 22% (14–31%) 20% (9–32%) 22% (12–32%)
NNT 6 (4–11) 4 (3–6) 4 (3–7) 5 (3–12) 5 (3–8)
Social function
ARR NS 30% (16–44%) 26% (11–42%) 26% (12–40%) NS
NNT NS 3 (2–6) 4 (2–9) 4 (2–8) NS
Emotional role
ARR 34% (13–55%) 38% (19–55%) 42% (21–63%) 43% (25–62%) 40% (18–62%)
NNT 3 (2–7) 3 (2–5) 2 (2–5) 2 (1–5) 2 (1–5)
Mental health
ARR NS 20% (9–30%) 20% (12–28%) 17% (7–27%) NS
NNT NS 5 (3–11) 5 (3–8) 6 (4–14) NS
NS¼Data not included because the differences were not statistically significant.
Table 4 Results expressed as mean (95% confidence interval) of ARR and NNTat follow-up relative to baseline in
patients with neuromuscular diseases.
Category Follow-up time
3 months 6 months 9 months 12 months 18 months
Physical capacity
ARR 59% (38–79%) 65% (46–84%) 60% (37–82%) 49% (25–72%) 47% (22–72%)
NNT 2 (1–3) 2 (1–2) 2 (1–3) 2 (1–4) 2 (1–4)
Transition
ARR 11% (5–18%) 13% (8–18%) 12% (6–17%) NS NS
NNT 9 (6–22) 8 (6–13) 9 (6–17) NS NS
NS¼Data not included because the differences were not statistically significant.
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ALS are somewhat controversial. For example, Bach
et al.15 obtained good results with ventilation
treatment, since tracheostomy could be avoided
in most of their patients. In contrast, only 10% of
the patients in the series by Moss et al.16 appeared
to be satisfied with HMV.
In a previous study in patients with the same
characteristics, we attributed the initial improve-
ment in HRQL in the group with TWD and its
persistence over a protracted period to the
improvement in gas exchange and to the lower
grade of dyspnoea following the HMV treatment.8
Similarly, the better HRQL observed in patients
with NMD appeared to be related to the better
blood gases level found in these patients following
HMV. We proposed that the subsequent deteriora-
tion could be due to the decreases in FVC and FEV1
observed in the long-term follow-up on these
patients.8 From the results of the present study,
we are able to identify an additional variable that
can explain the improvement in HRQL; i.e., the
lower number of hospitalizations that result in both
groups of patients following the implementation of
HMV. However, we need to highlight the paradox-
ical finding that the decrease in the number of
hospitalizations for acute respiratory failure in the
patients with NMD was noticeable, although their
HRQL was worse than that of patients with TWD.
Conversely, the TWD patient group had a much
better HRQL than the patients with NMD, but
required more hospitalizations, albeit fewer than
before implementation of the HMV treatment. At
present, it seems difficult to explain this finding.
Additional factors may have contributed to the
improved HRQL and hospitalization rates achieved
with the HMV treatment, such as the regular
follow-up and telephone consultation available to
all the patients undergoing the treatment. How-
ever, we must remark that outpatient appoint-
ments were similar pre- and post-HMV and records
of the telephone calls indicated that most were
related to technical aspects of the equipment.
The lack of a control group and the relatively
small number of patients included in the present
trial constitute the principal limitations of the
study. However, ethical constraints preclude us
withholding the clearly efficacious treatment from
these types of patients merely to have control-
group data available. In addition, the frequent and
protracted follow-up could compensate for the
relatively small numbers of patients studied.
In conclusion, we believe that HMV is a procedure
that improves HRQL in patients with restrictive
respiratory diseases, especially those suffering
from TWD and this finding is long lasting. In
contrast, HRQL does not show such improvement
in NMD patients and this amelioration is shorter.
However, patients with NMD had a reduced number
of hospitalizations together with a better ARR and
NNT than did patients suffering from TWD. Given
that these changes are highly relevant for these
patients, we consider that the HMV is a suitable
therapy for most patients suffering from restrictive
respiratory diseases.
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